Imagine that, 30 years or so working on this hypothesis and all the progress on molecular level and preclinical stage defining the exact ways how PKC epsilon works.
And finally he gets to see some definitive clinical data that will hopefully turn the entire industry upside down.
If the Phase 2 confirmation trial reads out as we expect it to I would think that Dr. Alkon’s efforts would deserve a Noble nomination. He will also be extremely wealthy as will anyone who owns even a small piece of this company.